Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADIR Trial: High-Dose Nicotinamide in Primary Open-Angle Glaucoma
NCT07808333Phase 2Not yet recruiting
- Sponsor
- University of Chicago
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nicotinamide in primary open-angle glaucoma (POAG) (2 arms), sponsored by University of Chicago. Primary endpoint: Annualized Rate of Macular Ganglion Cell-Inner Plexiform Layer (GCIPL) Thinning at 12 months. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
nicotinamide
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT07808333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07808333.